Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Roche, Catalent
Roche Comes Out Against Allowing Takeover of Drug Manufacturer Catalent
Last week, U.S. consumer groups and labour unions petitioned the U.S. Federal Trade Commission to block Novo Holdings, the controlling shareholder of Novo Nordisk, from acquiring Catalent, saying the deal threatened competition in weight loss drugs and cutting-edge gene therapies.
Roche CEO says Novo's Catalent buyout 'could be a problem' for smaller drugmakers
The groups behind the letter alleged that Novo Nordisk’s plant purchases could hinder not only the Danish drugmaker’s chief commercial rival, Eli Lilly, but also companies like Viking Therapeutics, Pfizer, Roche and AstraZeneca, who are working on their own metabolic offerings.
Roche CEO says antitrust regulators should block Catalent sale to Novo Foundation
The CEO of Swiss pharmaceuticals behemoth Roche (OTCQX:RHHBY) said he believes antitrust regulators should not allow Novo Nordisk Foundation's to purchase Catalent (NYSE:CTLT). "It's not a problem for us,
Roche CEO Urges FTC to Block Novo Nordisk's Acquisition of Catalent
Roche CEO Urges FTC to Block Novo Nordisks Acquisition of Catalent Roches CEO, Thomas Schinecker, has called on authorities to prevent Novo Nordisks controlling shareholder, Novo Holdings, from acquiring contract
Roche comes out against clearing takeover of drug manufacturer Catalent
The CEO of pharmaceuticals giant Roche has urged authorities to block the takeover of contract drug manufacturer Catalent by Novo Nordisk's controlling shareholder, citing harm to industry peers. "It's not a problem for us,
BioSpace
1d
Why It’s OK to Talk About Catalent’s Pending Buyout by ‘Novo’
The group of like-named companies that include Novo Holdings and Novo Nordisk—the two tied to a multibillion-dollar buyout of ...
4d
on MSN
Catalent CEO to remain in charge of contract drugmaker after Novo Holdings' buyout
Catalent CEO Alessandro Maselli said on Monday he will remain at the helm of the U.S.-based contract drugmaker after it is ...
STAT
4d
Catalent tries to reassure customers about its deal with Novo Holdings
Catalent, a leading contract drug manufacturer, issued an open letter Monday to reassure customers that a proposed $16.5 ...
FiercePharma
7d
Novo Holdings' $16.5B Catalent buyout in crosshairs as consumer groups ask FTC to block the deal
Novo Holdings is encountering more resistance as it aims to close its $16.5 billion acquisition of pharma manufacturing giant ...
1d
on MSN
Roche seeks to block Novo Nordisk's Catalent deal over weight-loss drug competition
FRANKFURT: The CEO of pharmaceuticals giant Roche, opens new tab said authorities should block the takeover of contract drug ...
STAT
1d
Pfizer’s activist troubles, gene therapy questions, RFK Jr.’s MAHA ambitions
STAT's Readout LOUD podcast discusses Pfizer's woes, explains RFK Jr.'s 'MAHA' campaign, and mulls the latest about the Novo ...
devdiscourse
1d
Pharmaceutical Shifts and Health Innovations: A Global Perspective
Current health news covers Roche's opposition to Catalent's takeover, cost analysis of weight-loss drugs like Wegovy, U.S.
7d
Consumer groups ask FTC to block Novo Holdings-Catalent deal
U.S. consumer groups and two large labor unions urged the U.S. Federal Trade Commission on Thursday to block Novo Holdings, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback